esketamine

Showing 6 posts of 6 posts found.

spravato

New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

May 21, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …

5789851635_d493d41b35_z

Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression

March 21, 2019
Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs

The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …

spravato

Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years

March 6, 2019
Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma

The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10

News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …

janssen_latest_logo_on_sign_closer

Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …

jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

Latest content